SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sordet, O. Articles by Solary, E. Search for Related Content PubMed PubMed Citation Articles by Sordet, O. Articles by Solary, E. Related Collections Neoplasia Apoptosis Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 June 2001, Vol. 97, No. 12, pp. 3931-3940 NEOPLASIA Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis Olivier Sordet, Cédric Rébé, Ingrid Leroy, Jean-Marie Bruey, Carmen Garrido, Carole Miguet, Gérard Lizard, Stéphanie Plenchette, Laurent Corcos, and Eric Solary From the Faculty of Medicine and Pharmacy, INSERM U517 and INSERM U498, IFR 100, Dijon, France. Exposure of U937 human leukemic cells to the phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) induces their differentiation into monocyte/macrophage-like cells. This terminal differentiation is associated with a resistant phenotype to apoptosis induced by the topoisomerase II inhibitor etoposide. The inhibition occurs upstream of the mitochondrial release of cytochrome c and the activation of procaspase-2, -3, -6, -7, -8, and -9. By using cell-free systems, it was demonstrated that the mitochondrial pathway to cell death that involves mitochondrial membrane depolarization, cytochrome c release and cytosolic activation of procaspases by cytochrome c/dATP remains functional in TPA-differentiated U937 cells. Accordingly, 2 drugs recently shown to target the mitochondria, namely lonidamine and arsenic trioxide, bypass the resistance of TPA-differentiated U937 cells to classical anticancer drugs. Cell death induced by the 2 compounds is associated with mitochondrial membrane depolarization, release of cytochrome c and Smac/Diablo from the mitochondria, activation of caspases, poly(ADP-ribose) polymerase cleavage and internucleosomal DNA fragmentation. Moreover, the decreased glutathione content associated with the differentiation process amplifies the ability of arsenic trioxide to activate the mitochondrial pathway to cell death. Similar results were obtained by comparing undifferentiated and TPA-differentiated human HL60 leukemic cells. These data demonstrate that mitochondria-targeting agents bypass the resistance to classical anticancer drugs induced by TPA-mediated leukemic cell differentiation. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. H. Kim, J. H. Kim, Y. S. Yu, D. H. Kim, C. J. Kim, and K.-W. Kim Antitumor Activity of Arsenic Trioxide on Retinoblastoma: Cell Differentiation and Apoptosis Depending on Arsenic Trioxide Concentration Invest. Ophthalmol. Vis. Sci., April 1, 2009; 50(4): 1819 - 1823. [Abstract] [Full Text] [PDF] G. Martin, N. Cagnon, O. Sabido, B. Sion, G. Grizard, P. Durand, and R. Levy Kinetics of occurrence of some features of apoptosis during the cryopreservation process of bovine spermatozoa Hum. Reprod., February 1, 2007; 22(2): 380 - 388. [Abstract] [Full Text] [PDF] P.-Y. Chang and S. Miyamoto Nuclear Factor-{kappa}B Dimer Exchange Promotes a p21waf1/cip1 Superinduction Response in Human T Leukemic Cells Mol. Cancer Res., February 1, 2006; 4(2): 101 - 112. [Abstract] [Full Text] [PDF] N. Karasavvas, J. M. Carcamo, G. Stratis, and D. W. Golde Vitamin C protects HL60 and U266 cells from arsenic toxicity Blood, May 15, 2005; 105(10): 4004 - 4012. [Abstract] [Full Text] [PDF] A. M. Ramos, C. Fernandez, D. Amran, P. Sancho, E. de Blas, and P. Aller Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells Blood, May 15, 2005; 105(10): 4013 - 4020. [Abstract] [Full Text] [PDF] L. Berthoux, S. Sebastian, E. Sokolskaja, and J. Luban Lv1 Inhibition of Human Immunodeficiency Virus Type 1 Is Counteracted by Factors That Stimulate Synthesis or Nuclear Translocation of Viral cDNA J. Virol., November 1, 2004; 78(21): 11739 - 11750. [Abstract] [Full Text] [PDF] S. Plenchette, S. Cathelin, C. Rebe, S. Launay, S. Ladoire, O. Sordet, T. Ponnelle, N. Debili, T.-H. Phan, R.-A. Padua, et al. Translocation of the inhibitor of apoptosis protein c-IAP1 from the nucleus to the Golgi in hematopoietic cells undergoing differentiation: a nuclear export signal-mediated event Blood, October 1, 2004; 104(7): 2035 - 2043. [Abstract] [Full Text] [PDF] O. Sordet, Z. Liao, H. Liu, S. Antony, E. V. Stevens, G. Kohlhagen, H. Fu, and Y. Pommier Topoisomerase I-DNA Complexes Contribute to Arsenic Trioxide-induced Apoptosis J. Biol. Chem., August 6, 2004; 279(32): 33968 - 33975. [Abstract] [Full Text] [PDF] G. Martin, O. Sabido, P. Durand, and R. Levy Cryopreservation Induces an Apoptosis-Like Mechanism in Bull Sperm Biol Reprod, July 1, 2004; 71(1): 28 - 37. [Abstract] [Full Text] [PDF] C. Fernandez, A. M. Ramos, P. Sancho, D. Amran, E. de Blas, and P. Aller 12-O-Tetradecanoylphorbol-13-acetate May Both Potentiate and Decrease the Generation of Apoptosis by the Antileukemic Agent Arsenic Trioxide in Human Promonocytic Cells: REGULATION BY EXTRACELLULAR SIGNAL-REGULATED PROTEIN KINASES AND GLUTATHIONE J. Biol. Chem., January 30, 2004; 279(5): 3877 - 3884. [Abstract] [Full Text] [PDF] H. H. Yang, M. H. Ma, R. A. Vescio, and J. R. Berenson Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis J. Clin. Oncol., November 15, 2003; 21(22): 4239 - 4247. [Abstract] [Full Text] [PDF] P. Papaldo, M. Lopez, E. Cortesi, E. Cammilluzzi, M. Antimi, E. Terzoli, G. Lepidini, P. Vici, C. Barone, G. Ferretti, et al. Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide J. Clin. Oncol., September 15, 2003; 21(18): 3462 - 3468. [Abstract] [Full Text] [PDF] L. Berthoux, G. J. Towers, C. Gurer, P. Salomoni, P. P. Pandolfi, and J. Luban As2O3 Enhances Retroviral Reverse Transcription and Counteracts Ref1 Antiviral Activity J. Virol., March 1, 2003; 77(5): 3167 - 3180. [Abstract] [Full Text] [PDF] O. Sordet, C. Rebe, S. Plenchette, Y. Zermati, O. Hermine, W. Vainchenker, C. Garrido, E. Solary, and L. Dubrez-Daloz Specific involvement of caspases in the differentiation of monocytes into macrophages Blood, December 15, 2002; 100(13): 4446 - 4453. [Abstract] [Full Text] [PDF] J. L. Slack, S. Waxman, G. Tricot, M. S. Tallman, and C. D. Bloomfield Advances in the Management of Acute Promyelocytic Leukemia and Other Hematologic Malignancies with Arsenic Trioxide Oncologist, April 1, 2002; 7(90001): 1 - 13. [Abstract] [Full Text] [PDF] W. H. Miller Jr. Molecular Targets of Arsenic Trioxide in Malignant Cells Oncologist, April 1, 2002; 7(90001): 14 - 19. [Abstract] [Full Text] [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020